Humira "Dear Doctor" Letter Emphasizes Class Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's letter reinforces the class warning concerning combination use of Amgen's Kineret and another TNF-inhibitor, the company says. Revised labeling for Humira also includes new warnings regarding hypersensitivity reactions and hematologic events.